NM_017705.4:c.-115-2252C>T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_017705.4(PAQR5):c.-115-2252C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.806 in 152,118 control chromosomes in the GnomAD database, including 52,347 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.81 ( 52347 hom., cov: 33)
Consequence
PAQR5
NM_017705.4 intron
NM_017705.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.0470
Publications
7 publications found
Genes affected
PAQR5 (HGNC:29645): (progestin and adipoQ receptor family member 5) Predicted to enable signaling receptor activity. Predicted to be involved in oogenesis. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.954 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PAQR5 | NM_017705.4 | c.-115-2252C>T | intron_variant | Intron 2 of 8 | ENST00000395407.7 | NP_060175.3 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PAQR5 | ENST00000395407.7 | c.-115-2252C>T | intron_variant | Intron 2 of 8 | 1 | NM_017705.4 | ENSP00000378803.2 | |||
| PAQR5 | ENST00000561153.5 | c.-115-2252C>T | intron_variant | Intron 2 of 8 | 5 | ENSP00000453526.1 | ||||
| PAQR5 | ENST00000558684.5 | c.-82+20213C>T | intron_variant | Intron 2 of 4 | 5 | ENSP00000453009.1 |
Frequencies
GnomAD3 genomes AF: 0.806 AC: 122537AN: 152000Hom.: 52335 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
122537
AN:
152000
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.806 AC: 122578AN: 152118Hom.: 52347 Cov.: 33 AF XY: 0.804 AC XY: 59839AN XY: 74390 show subpopulations
GnomAD4 genome
AF:
AC:
122578
AN:
152118
Hom.:
Cov.:
33
AF XY:
AC XY:
59839
AN XY:
74390
show subpopulations
African (AFR)
AF:
AC:
20934
AN:
41416
American (AMR)
AF:
AC:
12383
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
AC:
3322
AN:
3472
East Asian (EAS)
AF:
AC:
3765
AN:
5178
South Asian (SAS)
AF:
AC:
4530
AN:
4818
European-Finnish (FIN)
AF:
AC:
9429
AN:
10610
Middle Eastern (MID)
AF:
AC:
267
AN:
294
European-Non Finnish (NFE)
AF:
AC:
65322
AN:
68032
Other (OTH)
AF:
AC:
1785
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
921
1843
2764
3686
4607
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
850
1700
2550
3400
4250
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2810
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.